Cargando…

The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia

PURPOSE: Refractory pediatric leukemia remains one of the leading causes of death in children. Intensification of current chemotherapy regimens to improve the outcome in these children is often limited by the effects of drug resistance and cumulative toxicity. Hence, the search for newer agents and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meier-Stephenson, Vanessa, Riemer, Justin, Narendran, Aru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440076/ https://www.ncbi.nlm.nih.gov/pubmed/28553123 http://dx.doi.org/10.2147/OTT.S136484

Ejemplares similares

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir
por: Subeha, Mahbuba R., et al.
Publicado: (2020)

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
por: Yamamoto, Norio, et al.
Publicado: (2004)

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors
por: Blumenthal, Gideon M., et al.
Publicado: (2014)

New Insights into the In Silico Prediction of HIV Protease Resistance to Nelfinavir
por: Antunes, Dinler A., et al.
Publicado: (2014)

Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir
por: Grigorian, Aline, et al.
Publicado: (2008)

Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity
por: Koltai, Tomas
Publicado: (2015)

Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
por: Besse, Lenka, et al.
Publicado: (2021)

Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer
por: Guan, Min, et al.
Publicado: (2015)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Nelfinavir, an HIV-1 Protease Inhibitor, Induces Oxidative Stress–Mediated, Caspase-Independent Apoptosis in Leishmania Amastigotes
por: Kumar, Pranav, et al.
Publicado: (2010)

The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia
por: Sharma, Ritul, et al.
Publicado: (2023)

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein
por: Liu, Zhongli, et al.
Publicado: (2022)

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
por: Wilson, James M., et al.
Publicado: (2016)

Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents
por: Jayanthan, Aarthi, et al.
Publicado: (2014)

Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir
por: Bolcato, Giovanni, et al.
Publicado: (2020)

The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents
por: Grundy, Megan, et al.
Publicado: (2022)

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo
por: Liebscher, Steffi, et al.
Publicado: (2017)

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect
por: Foo, Caroline S., et al.
Publicado: (2022)

Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease
por: Gupta, Ankita, et al.
Publicado: (2015)

Induction of Suicidal Erythrocyte Death by Nelfinavir
por: Bissinger, Rosi, et al.
Publicado: (2015)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023)

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children
por: Resino, Salvador, et al.
Publicado: (2006)

Effect of nelfinavir stereoisomers on coronavirus main protease: Molecular docking, molecular dynamics simulation and MM/GBSA study
por: Sargolzaei, Mohsen
Publicado: (2021)

Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition
por: Jayanthan, Aarthi, et al.
Publicado: (2011)

Nelfinavir: An Old Ally in the COVID-19 Fight?
por: Gidari, Anna, et al.
Publicado: (2022)

Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma
por: Swift, Lucy, et al.
Publicado: (2019)

Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia
por: Chang, Yoon Soo, et al.
Publicado: (2023)

Bilateral uveitis associated with concurrent administration of rifabutin and nelfinavir
por: Cheng, Wen-Hsin, et al.
Publicado: (2015)

Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect
por: Venkatesh, D. Nagasamy, et al.
Publicado: (2015)

Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape
por: Theys, Kristof, et al.
Publicado: (2010)

Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia
por: Kang, S M, et al.
Publicado: (2017)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells
por: Brüning, Ansgar, et al.
Publicado: (2010)

Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2
por: Xu, Zhijian, et al.
Publicado: (2023)

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
por: Reynolds, Carson R., et al.
Publicado: (2022)

The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
por: Kwo, Paul Y., et al.
Publicado: (2011)

Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept(®), Roche): overview
por: Pozniak, Anton, et al.
Publicado: (2009)

Oxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer Cells
por: Soprano, Maria, et al.
Publicado: (2016)

The Effect of β-Carotene Supplementation on the Pharmacokinetics of Nelfinavir and Its Active Metabolite M8 in HIV-1-infected Patients
por: Sheehan, Nancy L., et al.
Publicado: (2012)

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia
por: Hoeksema, Kimberley A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_v5fcp6l8sibc7koi5r8qjsj1dr